National Aeronautics and Space Administration December 21, 2005 – Federal Register Recent Federal Regulation Documents

This notice is issued in accordance with 35 U.S.C. 209(c)(1) and 37 CFR 404.7(a)(1)(i). NASA hereby gives notice of its intent to grant a partially exclusive license in the United States to practice the inventions described and claimed in Foreign Patent No. 0423277, JSC Docket No. MSC-21293-1-EP, ``Bio-Reactor Cell Culture Process'', Foreign Patent No. 1987294, JSC Docket No. MSC-21293-1-JP, ``Bio- Reactor Cell Culture Process'', International Application No. PCT/US98/ 06826, JSC Docket No. MSC-22859-1-EP, European Application No. 98915320.0 entitled ``Production of Functional Proteins: Balance of Shear Stress and Gravity'', International Application No. PCT/US98/ 06826, JSC Docket No. MSC-22859-1-JP, Japanese Application No. 10- 540983 entitled ``Production of Functional Proteins: Balance of Shear Stress and Gravity'', International Application No. PCT/US98/06826, JSC Docket No. MSC-22859-1-CA, Canadian Application No. 2286349 entitled ``Production of Functional Proteins: Balance of Shear Stress and Gravity'', International Application No. PCT/US98/06826, JSC Docket No. MSC-22859-1-IL, Israeli Application No. 132264 entitled ``Production of Functional Proteins: Balance of Shear Stress and Gravity'', International Application No. PCT/US98/06826, JSC Docket No. MSC-22859- 1-MX, Mexican Application No. 999265 entitled ``Production of Functional Proteins: Balance of Shear Stress and Gravity'', and International Application No. PCT/US98/06826, JSC Docket No. MSC-22859- 1-BR, Brazilian Application No. 98915320.0 entitled ``Production of Functional Proteins: Balance of Shear Stress and Gravity'' to Renautus Bio Therapeutics, LLC, having its principal place of business in Baton Rouge, LA. The patent rights in the inventions have been assigned to the United States of America as represented by the Administrator of the National Aeronautics and Space Administration. The prospective partially exclusive license will comply with the terms and conditions of 35 U.S.C. 209 and 37 CFR 404.7.